Template:Antibiotics Ludwigs Immunocompromised: Difference between revisions

(Prepared the page for translation)
Line 1: Line 1:
<languages/>
<translate>
====Immunocompromised<ref>Spitalnic SJ, Sucov A. Ludwig's angina: case report and review. J Emerg Med. 1995;13:499-503</ref>====
====Immunocompromised<ref>Spitalnic SJ, Sucov A. Ludwig's angina: case report and review. J Emerg Med. 1995;13:499-503</ref>====
*[[Cefepime]] 2 g IV q12 hrs + [[Metronidazole]] 500 mg IV q6 hrs OR
 
*[[Meropenem]] 1 g IV q8 hrs OR
*[[Special:MyLanguage/Cefepime|Cefepime]] 2 g IV q12 hrs + [[Special:MyLanguage/Metronidazole|Metronidazole]] 500 mg IV q6 hrs OR
*[[Imipenem/Cilastatin]] 500mg (20mg/kg) IV q6 hours
*[[Special:MyLanguage/Meropenem|Meropenem]] 1 g IV q8 hrs OR
*[[Piperacillin-tazobactam]] 4.5g (80mg/kg) IV q6 hours
*[[Special:MyLanguage/Imipenem/Cilastatin|Imipenem/Cilastatin]] 500mg (20mg/kg) IV q6 hours
*Add [[Vancomycin]] 15-20 mg/kg IV q8 hrs (max 2 g per dose) if concern for MRSA risk factors
*[[Special:MyLanguage/Piperacillin-tazobactam|Piperacillin-tazobactam]] 4.5g (80mg/kg) IV q6 hours
*Add [[Special:MyLanguage/Vancomycin|Vancomycin]] 15-20 mg/kg IV q8 hrs (max 2 g per dose) if concern for MRSA risk factors
</translate>

Revision as of 08:23, 23 January 2026

Other languages:

Immunocompromised[1]

  1. Spitalnic SJ, Sucov A. Ludwig's angina: case report and review. J Emerg Med. 1995;13:499-503